Bionor is a biopharmaceutical company with first mover potential to advance a possible functional HIV cure

Latest news

Hide mandatory notifications of trade

H1 2016 Interim Financial Report

Financial .2016

BIONOR PHARMA ASA
INTERIM FINANCIAL REPORT
1 JANUARY – 30 JUNE 2016
UNAUDITED

Key information relating to the conditional rights offering to be carried out by Bionor Pharma ASA

Financial .2016

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES

Notice of Extraordinary General Meeting 9 September 2016

Financial .2016

(Oslo, Norway, 19 August 2016) An Extraordinary General Meeting of Bionor Pharma ASA will be held on Friday 9 September 2016 at 12:00 hours at Kronprinsesse Märthas Plass 1, Oslo, Norway in the 9th floor meeting room.

H1 2016 Interim Financial Report

Financial .2016

BIONOR PHARMA ASA
INTERIM FINANCIAL REPORT
1 JANUARY – 30 JUNE 2016
UNAUDITED

Key information relating to the conditional rights offering to be carried out by Bionor Pharma ASA

Financial .2016

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES

Notice of Extraordinary General Meeting 9 September 2016

Financial .2016

(Oslo, Norway, 19 August 2016) An Extraordinary General Meeting of Bionor Pharma ASA will be held on Friday 9 September 2016 at 12:00 hours at Kronprinsesse Märthas Plass 1, Oslo, Norway in the 9th floor meeting room.

Go to news section

Featured content